CorMedix (CRMD) Gains from Investment Securities (2015 - 2025)

CorMedix (CRMD) reported Gains from Investment Securities of -$2.3 million for Q4 2025, down 225381.57% sequentially from $1009.0 in Q1 2019.

CorMedix (CRMD) Gains from Investment Securities (2015 - 2025) Analysis & Trends

CorMedix (CRMD) has 5 years of Gains from Investment Securities data on file, last reported at -$2.3 million in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$2.3 million; the trailing twelve-month figure through Dec 2025 stood at -$2.3 million (changed N/A YoY), and the FY2025 full-year result was -$5.4 million, changed N/A from the prior year.
  • Gains from Investment Securities eased to -$2.3 million in Q4 2025, from $1009.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of -$2.3 million in Q4 2025 to a low of -$2.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 CorMedix 4.95 Mn -150.26 Mn 107.31 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -2.27 Mn
Dec 31, 2025 -2.27 Mn
Mar 31, 2019 1,009.00
Mar 31, 2019 1,009.00
Sep 30, 2017 2,600.00
Sep 30, 2017 2,600.00
Jun 30, 2017 10,203.00
Jun 30, 2017 10,203.00
Mar 31, 2017 210.00
Mar 31, 2017 210.00
Dec 31, 2016 -17,233.00
Dec 31, 2016 -17,233.00
Sep 30, 2016 -6,764.00
Sep 30, 2016 -6,764.00
Jun 30, 2016 23,997.00
Jun 30, 2016 23,997.00
Jun 30, 2015 -5,504.00
Jun 30, 2015 -5,504.00